These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9170118)

  • 1. Pathophysiology and psychopharmacology of dementia--a new study design. 2. Cyclandelate treatment--a placebo-controlled double-blind clinical trial.
    Schellenberg R; Todorova A; Wedekind W; Schober F; Dimpfel W
    Neuropsychobiology; 1997; 35(3):132-42. PubMed ID: 9170118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclandelate versus flunarizine. A double-blind study in a selected group of patients with dementia.
    Albizzati MG; Bassi S; Calloni E; Sbacchi M; Piolti R; Frattola L
    Drugs; 1987; 33 Suppl 2():90-6. PubMed ID: 3304956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclandelate in the treatment of senility: a controlled study.
    Capote B; Parikh N
    J Am Geriatr Soc; 1978 Aug; 26(8):360-2. PubMed ID: 353121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclandelate in the treatment of senile mental changes: a double-blind evaluation.
    Rao DB; Georgiev EL; Paul PD; Guzman AB
    J Am Geriatr Soc; 1977 Dec; 25(12):548-51. PubMed ID: 336670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and psychopharmacology of dementia--a new study design. I. Diagnosis comprising subjective and objective criteria.
    Schellenberg R; Todorova A; Dimpfel W; Schober F
    Neuropsychobiology; 1995; 32(2):81-97. PubMed ID: 7477806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
    Diener HC; Krupp P; Schmitt T; Steitz G; Milde K; Freytag S
    Cephalalgia; 2001 Feb; 21(1):66-70. PubMed ID: 11298666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients.
    Davies G; Hamilton S; Hendrickson E; Levy R; Post F
    Age Ageing; 1977 Aug; 6(3):156-62. PubMed ID: 331919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice.
    Blakemore CB
    Drugs; 1987; 33 Suppl 2():110-3. PubMed ID: 3622304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclandelate on dementia.
    Westreich G; Alter M; Lundgren S
    Stroke; 1975; 6(5):535-8. PubMed ID: 1101457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of cyclandelate on the CNS--a double-blind, placebo-controlled study of healthy subjects].
    Dimpfel W; Netter P; Spüler M; Wedekind W
    Klin Wochenschr; 1991 May; 69(7):313-9. PubMed ID: 2067317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study.
    Görtelmeyer R; Erbler H
    Arzneimittelforschung; 1992 Jul; 42(7):904-13. PubMed ID: 1418054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
    Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerance of cyclandelate versus pizotifen in the prophylaxis of migraine.
    Mastrosimone F; Iaccarino C; de Caterina G
    J Med; 1992; 23(1):1-16. PubMed ID: 1573338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclandelate in the prophylaxis of migraine: a randomized, parallel, double-blind study in comparison with placebo and propranolol. The Study group.
    Diener HC; Föh M; Iaccarino C; Wessely P; Isler H; Strenge H; Fischer M; Wedekind W; Taneri Z
    Cephalalgia; 1996 Oct; 16(6):441-7. PubMed ID: 8902255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propentofylline in adult-onset cognitive disorders: double-blind, placebo-controlled, clinical, psychometric and brain mapping studies.
    Saletu B; Möller HJ; Grünberger J; Deutsch H; Rössner M
    Neuropsychobiology; 1990-1991; 24(4):173-84. PubMed ID: 2135708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclandelate in diabetic neuropathy. A double-blind, placebo-controlled, randomized, cross-over study.
    Heimans JJ; Drukarch B; Matthaei I; Ijff GA; Bertelsmann FW; Strijers RL; Nauta J
    Acta Neurol Scand; 1991 Dec; 84(6):483-6. PubMed ID: 1665271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolytic activity of oral cyclandelate in patients with generalized atherosclerotic vasculopathy: a double-blind study.
    Forconi S; Cappelli R; Guerrini M; Frigerio C; Messa GL; Furesi L
    J Int Med Res; 1990; 18(4):257-65. PubMed ID: 2121564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.